Anxiety in children and adolescents with primary headaches: diagnosis and treatment options

Esin O.R.; Esin R.G.; Khayrullin I.Kh.

doi:https://doi.org/10.17116/jnevro202212209246

Esin O.R.

Kazan (Volga region) Federal University;
Clinic of Otorhinolaryngology

SPIN RSCI: 8012-3620
Scopus AuthorID: 35738650000
ORCID: 0000-0003-4244-4446

Esin R.G.

Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education;
Kazan (Volga Region) Federal University

SPIN RSCI: 6467-4374
Scopus AuthorID: 6602604025
ORCID: 0000-0001-6762-8845

Khayrullin I.Kh.

Kazan (Volga region) Federal University

ORCID: 0000-0003-0919-035X

Anxiety in children and adolescents with primary headaches: diagnosis and treatment options

Authors:

Esin O.R., Esin R.G., Khayrullin I.Kh.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9‑2): 46‑50

DOI: 10.17116/jnevro202212209246

Read: 3174 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Esin OR, Esin RG, Khayrullin IKh. Anxiety in children and adolescents with primary headaches: diagnosis and treatment options. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9‑2):46‑50. (In Russ.)
https://doi.org/10.17116/jnevro202212209246

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To determine the comorbidity of primary headaches (PH) and anxiety in adolescents and the effectiveness of aminophenylbutyric acid (Anvifen) in the treatment of anxiety (750 mg per day for 21 days).

MATERIAL AND METHODS

Group 1 — «episodic PH» (up to 15 days with headaches per month for 12 months) — 84 patients (mean age 15.5±1.3 years; 46.4% boys, 53.6% girls). Group 2 — «chronic PH» (15 days or more with headache per month for 12 months) — 55 patients (mean age 15.2±1.4 years; 44.3% boys, 55.7% girls). Group 3 — «teenagers without headache» (have not experienced pain in the last 6 months) — 67 people (mean age 15.7±1.4 years; 44.8% boys, 55.2% girls). Anxiety assessment using the Pediatric Anxiety Rating Scale (PARS): number of symptoms (patient); number of symptoms (expert); severity scale (expert); clinical examination (expert).

RESULTS

Before/after treatment: group 1 number of symptoms (patient) = 24 [23; 26]/9 [8; 10], number of symptoms (expert) = 23 [22; 25]/12 [12; 13], severity scale (expert) = 21 [20; 25]/9 [8; 11], clinical examination (expert) = 14 [13; 14]/9 [8; 9]; group 2 number of symptoms (patient) = 47 [46; 48]/43 [45; 47], number of symptoms (expert) = 40 [38; 41]/39 [38; 40], severity scale (expert) =33 [31; 34]/32 [31; 34], clinical examination (expert) = 20 [20; 22]/19 [19; 21].

CONCLUSION

Anxiety is a comorbid symptom in adolescents with PH, it is more pronounced in chronic PH. Anvifen has high efficacy in the treatment of anxiety comorbid with episodic PH, moderate efficacy in chronic PH. Treatment of anxiety in adolescents should begin as early as possible to prevent chronicity of the disease.

Keywords:

primary headaches

anxiety

adolescents

Pediatric Anxiety Rating Scale

Anvifen

Authors:

Esin O.R.

Kazan (Volga region) Federal University;
Clinic of Otorhinolaryngology

SPIN RSCI: 8012-3620
Scopus AuthorID: 35738650000
ORCID: 0000-0003-4244-4446

Esin R.G.

Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education;
Kazan (Volga Region) Federal University

SPIN RSCI: 6467-4374
Scopus AuthorID: 6602604025
ORCID: 0000-0001-6762-8845

Khayrullin I.Kh.

Kazan (Volga region) Federal University

ORCID: 0000-0003-0919-035X

Received:

24.05.2022

Accepted:

02.06.2022

Close metadata

References:

Rozenman M, Patarino K. Pediatric Anxiety in Practice: A Knowledge and Needs Assessment of Pediatricians and Nurses. J Develop Behav Pediatrics. 2020;41(8):605-611. https://doi.org/10.1097/DBP.0000000000000821
Ghandour R, Sherman L, Vladutiu C, et al. Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children. J Pediatr. 2019;206:256-267.e3. https://doi.org/10.1016/j.jpeds.2018.09.021
Changing face of americas adolescents. Opa.hhs.gov. Published 2022. Accessed January 15, 2022. https://opa.hhs.gov/adolescent-health?facts-and-stats/changing-face-of-americas-adolescents/index.html
Diagnostic And Statistical Manual Of Mental Disorders. Arlington, Va: American Psychiatric Association; 2013;189-233.
Regier D, Kuhl E, Kupfer D. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92-98. https://doi.org/10.1002/wps.20050
Cummings C, Caporino N, Kendall P. Comorbidity of anxiety and depression in children and adolescents: 20 years after. Psychol Bull. 2014;140(3):816-845. https://doi.org/10.1037/a0034733
Rapee R. Preschool Environment and Temperament as Predictors of Social and Nonsocial Anxiety Disorders in Middle Adolescence. J Am Acad Child Adol Psychiatry. 2014;53(3):320-328. https://doi.org/10.1016/j.jaac.2013.11.014
Bandelow B. Long term treatment of anxiety disorders. Eur Psychiatry. 2007;22:73. https://doi.org/10.1016/j.eurpsy.2007.01.282
Bennett S, Walkup J. Anxiety disorders in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course. Uptodate.com. Published 2022. Accessed January 15, 2022. https://www.uptodate.com/contents/anxiety-disorders-in-children-and-adolescents-epidemiology-pathogenesis-clinical-manifestations-and-course#!
Fearon P. Relation between headache in childhood and physical and psychiatric symptoms in adulthood: national birth cohort study. BMJ. 2001;322(7295):1145-1145. https://doi.org/10.1136/bmj.322.7295.1145
Egermark-Eriksson I. Prevalence of headache in swedish schoolchildren. Acta Paediatr. 1982;71(1):135-140. https://doi.org/10.1111/j.1651-2227.1982.tb09384.x
Perquin C, Hazebroek-Kampschreur A, Hunfeld J, et al. Chronic Pain Among Children and Adolescents: Physician Consultation and Medication Use. Clin J Pain. 2000;16(3):229-235. https://doi.org/10.1097/00002508-200009000-00008
Carlsson J, Larsson B, Mark A. Psychosocial Functioning in Schoolchildren With Recurrent Headaches. Headache J Head Face Pain. 1996;36(2):77-82. https://doi.org/10.1046/j.1526-4610.1996.3602077.x
Seshia S. Chronic Daily Headache in Children and Adolescents. Can J Neurol Sci/J Can des Sci Neurol. 2004;31(3):319-323. https://doi.org/10.1017/s0317167100003383
Mazzone L, Vitiello B, Incorpora G, Mazzone D. Behavioral and Temperamental Characteristics of Children and Adolescents Suffering from Primary Headache. Cephalalgia. 2006;26(2):194-201. https://doi.org/10.1111/j.1468-2982.2005.01015.x
Martin S, Smith M. Psychosocial Factors in Recurrent Pediatric Headache. Pediatr Ann. 1995;24(9):469-474. https://doi.org/10.3928/0090-4481-19950901-07
Waldie K. Physical and psychological correlates of primary headache in young adulthood: A 26 year longitudinal study. J Neurol Neurosurg Psychiatry. 2002;72(1):86-92. https://doi.org/10.1136/jnnp.72.1.86
Egger H, Angold A, Costello E. Headaches and Psychopathology in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. 1998;37(9):951-958. https://doi.org/10.1097/00004583-199809000-00015
Esin OR, Khairullin IKh, Esin RG, Tokareva NV. Tension type headache: GABA-ergic drug anvifen efficacy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):58-61. (In Russ.). https://doi.org/10.17116/jnevro20161162158-61
The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1061-1069. https://doi.org/10.1097/00004583-200209000-00006
Esin OR. Diagnostika pervichnyh golovnyh bolej i komorbidnyh sostoyanij u detej: ucheb.-metod. posobie. Kazan’: Izdatel’stvo Kazanskogo universiteta; 2019;80. (In Russ.).
Caporino N, Brodman D, Kendall P, et al. Defining Treatment Response and Remission in Child Anxiety: Signal Detection Analysis Using the Pediatric Anxiety Rating Scale. J Am Acad Child Adolesc Psychiatry. 2013;52(1):57-67. https://doi.org/10.1016/j.jaac.2012.10.006
Ginsburg G, Keeton C, Drazdowski T, Riddle M. The Utility of Clinicians Ratings of Anxiety Using the Pediatric Anxiety Rating Scale (PARS). Child Youth Care Forum. 2010;40(2):93-105. https://doi.org/10.1007/s10566-010-9125-3
Carson N, Progovac A, Wang Y, Cook B. A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills. Depress Anxiety. 2017;34(12):1147-1156. https://doi.org/10.1002/da.22681
Perroud N. Suicidal Ideation during Antidepressant Treatment. CNS Drugs. 2011;25(6):459-471. https://doi.org/10.2165/11589420-000000000-00000
Esin RG, Esin OR, Khakimova AR. Effective neuroprotection and organ protection: activation of the endogenous mechanisms of sanogenesis. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):123-127. (In Russ.). https://doi.org/10.14412/2074-2711-2020-3-123-127
Korabel’nikova EA. Anxiety disorders in children with attention deficit/hyperactivity disorder. Russian Journal of Woman and Child Health. 2020;3(4):302-308. (In Russ.). https://doi.org/10.32364/2618-8430-2020-3-4-302-308
Esin O. Treatment of Tension-Type Headaches in Adolescents (14—15 Years Old): the Efficacy of Aminophenylbutyric Acid Hydrochloride. Bionanoscience. 2018;8(1):418-422. https://doi.org/doi:10.1007/s12668-018-0507-6
Surushkina SYu, Chutko LS, Yakovenko EA, et al. Features of emotional regulation in children with anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11-2):95-102. (In Russ.). https://doi.org/10.17116/jnevro202112111295
Lukushkina EF, Karpovich EI, Chaban OD. Aminofenilmasljanaja kislota (Anvifen): kliniko-farmakologicheskie aspekty i opyt primenenija v detskoj nevrologii. RMZh. 2014;22(3):228-231. (In Russ.).